导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.04% | 2614/4773 |
| 近一周 | -1.75% | 3229/5467 |
| 近一月 | -5.22% | 2243/5421 |
| 近一季 | -7.46% | 2354/5238 |
| 近半年 | -1.30% | 1894/4931 |
| 近一年 | 1.24% | 2301/4400 |
| 近两年 | 45.13% | 1639/2954 |
| 近三年 | 27.89% | 1151/2253 |
| 成立以来 | 42.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.60% 3303/4961 |
12.19% 2211/5312 |
- - |
- - |
| 2025 | 19.62% 2199/4813 |
-1.04% 2548/3635 |
2.16% 1801/4076 |
17.90% 2403/4524 |
0.36% 2045/4813 |
| 2024 | 15.95% 860/3463 |
2.67% 731/2808 |
-1.07% 917/3014 |
16.16% 1520/3129 |
-1.72% 1807/3463 |
| 2023 | -9.10% 1107/2656 |
4.16% 1034/2280 |
-3.91% 963/2385 |
-3.01% 824/2515 |
-6.36% 1736/2655 |
| 2022 | -19.02% 788/2207 |
-13.89% 862/1919 |
6.60% 650/2016 |
-13.36% 890/2113 |
1.81% 1129/2208 |
| 2021 | -2.07% 834/1822 |
-2.63% 682/1255 |
4.61% 865/1330 |
-5.29% 792/1466 |
1.51% 897/1822 |
| 2020 | 30.18% 525/1250 |
-9.64% 700/1028 |
13.06% 652/1067 |
12.75% 367/1164 |
13.02% 401/1184 |
| 2019 | 34.85% 390/1092 |
26.24% 422/739 |
-0.31% 242/788 |
0.55% 508/850 |
6.56% 595/918 |
| 2018 | - - |
- - |
- - |
-0.93% 212/660 |
-11.99% 391/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 万家中证港股通创新药ETF | 1.6293 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6918 | 32.17% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 港股通医疗ETF工银 | 0.9798 | 31.81% |
| 港股通医疗ETF华宝 | 0.9918 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4193 | 31.06% |
| 平安300ETF联接C VS. 长安沪深300非周期A(740101) |